Clinical Trial

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-02-21; most recent amendment 2026-07-27.
Trial Details
NCT Number NCT05263050
Lead Sponsor Fox Chase Cancer Center
Collaborators: Exelixis
Conditions Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Carcinoid Tumor
Enrollment 111 participants
Start Date 2022-01-21
Primary Completion 2026-12 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-28